发明名称 Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo
摘要 The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.
申请公布号 US8916155(B2) 申请公布日期 2014.12.23
申请号 US201213657499 申请日期 2012.10.22
申请人 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten 发明人 Kroczek Richard
分类号 A61K39/395;C07K16/28;A61K39/00 主分类号 A61K39/395
代理机构 Clark & Elbing LLP 代理人 Clark & Elbing LLP
主权项 1. A method of treating a T cell mediated allergic, inflammatory, or autoimmune disease, said method comprising administering to a patient an anti-ICOS antibody, or an ICOS-binding fragment thereof, wherein said antibody, or binding fragment thereof, once bound to ICOS expressed on the surface of cells results in the in vivo depletion of the cells to which it is bound.
地址 Berlin DE